Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Summarize this article with:
SA Transcripts157.39K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome December 15, 2025 8:00 AM EST Company Participants Jessica SerraWarner Biddle - CEO & DirectorNaji Gehchan - Chief Medical & Development Officer Conference Call Participants Lut Ming Cheng - JPMorgan Chase & Co, Research DivisionAmanda PiquetThomas Smith - Leerink Partners LLC, Research DivisionMichael Ulz - Morgan Stanley, Research DivisionDerek Archila - Wells Fargo Securities, LLC, Research DivisionSamantha Corwin - William Blair & Company L.L.C., Research DivisionKatherine Degen Presentation Operator Good morning, and welcome to the Kyverna Therapeutics Investor Conference Call. [Operator Instructions] Please note that this call is being recorded. I would now like to introduce Jessica Serra, Head of Investor Relations at Kyverna Therapeutics.
Jessica Serra Good morning, and thank you for joining today's conference call to discuss top line data from our KYSA-8 registrational trial of mivocabtagene autoleucel or miv-cel, formerly referred to as KYV-101 in patients with stiff person syndrome or SPS. Before we begin, I encourage everyone to visit the Investor Relations section of our website where you can find today's press release and presentation materials. I'd like to remind everyone that we will be making forward-looking statements during today's call. These statements reflect our current expectations and beliefs and are subject to risks and uncertainties that may cause actual results to differ materially. Please review the risk factors discussed in today's press release, our presentation materials and in our filings with the SEC for additional information. On the call today with prepared remarks are Warner Biddle, our Chief Executive Officer; and Naji Gehchan, our Chief Medical and Development Officer. For our Q&A session, we will be joined by Marc Grasso, our Chief Financial Officer; Sham Dholakia, our Chief Product Officer; and Dr. Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz as well